Token Cycle Example

Token Cycle Example

App users fill in the surveys in the Longevity app, and are rewarded in tokens that Rejuve has received from the sale of Product NFT shards. They can use their tokens to buy more in depth tests such as a DNA methylation profile, which gives them an opportunity to import more data, which again yields more tokens. They can then buy supplements with those tokens and report back over time with their subjective reaction and objective biometric tests, again paid for with tokens – the resulting reports being worth more tokens because they make the Rejuve AI even more accurate.

A lab/researcher/research entity has entered their identity token to register on the app/website and requests a certain kind of user data for data mining. It can add a user feature filter to study a particular demographic group or particular condition. The lab puts a filter in the Rejuve app/website and the request goes to each of the users matching the filter. The users are given the name and reputation of the lab, and if they and the lab both approve, their Rejuve ID enables the user data to be sent to the Rejuve AI for analysis. The lab gets the aggregated result of a datamining run, a suggestion for a new substance, and a product UID. The lab explores possible substances with an interactive series of runs of the AI, each with different feature filters, narrowing down the substance of interest in transactions with new groups of patients, the same lab ID, and the same product UID. Each run records each user's proportionate contribution, as calculated by the AI. Once the Lab has committed to a product, Rejuve Product NFT shards are minted for each user and weighted by the value of the data for each user created at the end of the AI study. Labs propose research based on this knowledge in Rejuve token transactions. This research becomes contributed data, and Product NFT shards are given to them as well.

Product owners vote on which longevity clinic will complete Phase 1 trials. Products that have completed research proposals are advertised for Phase 1 trials in the app/website. Underneath, the Rejuve tokens still retain the record of the proportionate credits assigned by the AI to all who contributed (or bought contributions) to the product. Longevity clinic physicians who want help from Rejuve in trials, supply willing patients and help create aggregate data. When they submit this data, they receive newly-minted Product NFT shards that associate their Data NFTs to the product UID, and grant them a negotiated portion of ownership. These physicians monitor the newly chosen research trial patients, monitoring the safety and efficacy of the treatment throughout the Phase 1 trial.

Successful Phase 1 trials then advertise for an in-network pharmaceutical company to take the product through Phase 2 and Phase 3, all the way to FDA approval and sales in pharmacies. Product owners vote on which pharmaceutical company conducts Phase 2 and Phase 3 trials, with their votes weighted in proportion to their pNFT shard ownership. Approved distributors buy treatments with tokens, and these tokens go to the owners, with the allocation of tokens to the data owners being negotiated based on the market value of the product outside the network.

Perhaps in the future, another lab may use the Rejuve AI to analyze data from all who give permission, using some larger data set combined with the smaller new successful Phase 1 clinical trial, to hypothesize yet another substance. If it goes through trials and FDA approval again, app users receive a second set of token rewards for the same data.